Fundamental Data for MNKD

MANNKIND C(NSDQ:MNKD)

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company''s lead product, the Technosphere Insulin System, consists of the Company''s dry-powder Technosphere formulation of insulin and the Company''s MedTone inhaler through which the powder is inhaled into the deep lung.

# Employees: 580

Address: 28903 North Avenue Paine,Valencia,CA,USA

Phone: 661 775-5300

Fax: 661 775-2080

Website: www.mannkindcorp.com

Email: ir@mannkindcorp.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Alfred E. Mann (Chmn.; C.E.O.)

Hakan S. Edstrom (Presi.; C.O.O.; Dir.)

Richard L. Anderson (Corp. V.P.; C.F.O.)

Ronald J. Consiglio (Dir.)

Michael Friedman M.D. (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/16/2010

Mean EPS (Next Qtr): ($0.41)

Mean EPS (Year): ($1.94)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 6

Shares Performance

Period	MNKD	Compare to S&P
YTD	100.58 %	66.01 %
4 Weeks	26.47 %	25.10 %
12 Weeks	-13.24 %	-18.20 %

Shares Information

Analyst Coverage: Y

Avg Volume: 1571151

Shares Outstanding: 111M

Market Cap: $0.76B

52 Week High: $11.81

52 Week Low: $2.02

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 MNKD split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 22.22 %

EPS Growth in Last Year: 37.31 %

Sales Growth in Last Quarter: -0.01 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: -0.010